As sleep disturbances have been reported in spinocerebellar ataxias (SCAs), including types SCA1, SCA2, SCA3, SCA6 and SCA13, identification and management of these disturbances can help minimise their impact on SCA patients' overall body functions and quality of life. To our knowledge, there are no studies that investigate sleep disturbances in SCA10. Therefore, the aim of this study was to assess sleep disturbances in patients with SCA10. Twenty-three SCA10 patients and 23 healthy controls were recruited. Patients were evaluated in terms of their demographic and clinical data, including disease severity (Scale for the Assessment and Rating of Ataxia, SARA) and excessive daytime sleepiness (Epworth Sleepiness Scale, ESS), and underwent polysomnography. SCA10 patients had longer rapid eye movement (REM) sleep (p = .04) and more REM arousals than controls (p< .0001). There was a correlation of REM sleep onset with the age of onset of symptoms (r = .459), and with disease duration (r = À.4305). There also was correlation between the respiratory disturbance index (RDI) and SARA (r = À.4013), and a strong indirect correlation between arousal index and age at onset of symptoms (r = À.5756). In conclusion, SCA10 patients had sleep abnormalities that included more REM arousals and higher RDI than controls. Our SCA10 patients had sleep disorders related to shorter disease duration and lower severity of ataxia, in a pattern similar to that of other neurodegenerative diseases.
| INTRODUCTION
Spinocerebellar ataxias (SCAs) comprise a large, complex group of heterogeneous autosomal dominant diseases characterised by progressive degeneration of the cerebellum and its afferent and efferent connections (Teive & Ashizawa, 2015) . In most areas of the world where the condition has been studied, the prevalence of a particular SCA type varies widely according to the ethnic distribution (Teive & Ashizawa, 2015) . An increasing number of SCA subtypes have been identified, and these have now been mapped to 43 different loci.
The most common form of the disease worldwide is SCA3, or Machado-Joseph disease. SCA10 is a rare form found predominantly in regions of Latin America, particularly Mexico and Brazil, where it is the second most common type (Matsuura et al., 2000; Teive & Ashizawa, 2013; Teive et al., 2004) . SCA10 is caused by an ATTCT pentanucleotide repeat expansion in intron 9 of the ATXN10 gene on chromosome 22q 13.1. This gene encodes a 450 kD protein of largely undetermined function. In the normal population, the number of ATTCT repeats ranges from 10 to 32, whereas in SCA10 patients the abnormally expanded allele contains 800-4500 repeats (Matsuura et al., 2000; Teive & Ashizawa, 2015; Teive et al., 2004) . Clinically, SCA10 patients presented with cerebellar ataxia, dysarthria, abnormal eye movements and seizures. However, the main phenotype observed in Brazilian SCA10 patients is pure cerebellar ataxia (Matsuura et al., 2000; Teive & Ashizawa, 2013; Teive & Ashizawa, 2015 ; Teive et al., 2004 Teive et al., , 2011 .
As sleep disturbances have been reported in SCAs, including types SCA1, SCA2, SCA3, SCA6 and SCA13, identification and management of these disturbances can help minimise their impact on SCA patients' overall body functions and quality of life (D'Abreu et al., 2009; Dang & Cunnington, 2010; Howell, Mahowald, & Gomez, 2006; Kapoor & Greenough, 2015; Pedroso, Braga-Neto, Fel ıcio, Aquion, et al., 2011; Pedroso, Braga-Neto, Fel ıcio, Dutra, et al., 2011; . D'Abreu et al. (2009) demonstrated that sleep disorders are common in patients with SCA3, particularly the presence of insomnia, restless legs syndrome (RLS) and REM sleep behaviour disorder (RBD), as well as nocturnal cramps, snoring and sleep obstructive apnea (SOA). Pedroso, BragaNeto, Fel ıcio, Aquion, et al., (2011); Pedroso, Braga-Neto, Fel ıcio, Dutra, et al., (2011); showed that the frequency of RLS was 23% in SCA1, 18% in SCA2, 56.7% in SCA3 and 23.8% in SCA 6. In the same study, the frequency of RBD was 80% in SCA2 and 45.9% in SCA3, and SOA was detected in 22.6% of SCA3 patients. Sleep disorders have not been described in SCA10. In this study, we therefore sought to investigate sleep disorders in SCA10 patients.
| ME TH ODS

| Subjects and clinical protocols
Twenty-three patients, from six families, with a confirmed molecular A control group with 23 apparently healthy individuals matched for age, gender and body mass index (BMI) was also recruited at the same institution. The control subjects had no family members with ataxia and no sleep complaints or chronic pulmonary, neurological, psychiatric or cardiovascular disease and no history of drug abuse or use of hypnotic medications.
All study subjects were assessed using a standardised protocol in which demographic and clinical variables and data on general and neurological examinations were collected. On the day of the PSG, patients were assessed by neurologic examination, and any history of abnormal behaviours during sleep was obtained from the patients, their bed partners and their caregivers. Ataxia severity was rated using the validated Brazilian version of the Scale for the Assessment and Rating of Ataxia (SARA) (Schmitz-H€ u et al., 2006) . In addition, patients with SCA10 were assessed using the Epworth Sleepiness Scale (ESS). Patients with Epworth scores > 10 were considered to have excessive daytime sleepiness (EDS) (Johns, 1991) . Finally, patients were asked about sleep problems, the characteristics of their dreams and the presence of symptoms of RBD (Postuma, 2014 
| Statistical analysis
The Shapiro-Wilk and Shapiro-Francia normality tests were used to check if continuous variables were normally distributed. Differences in the means of normally distributed variables were tested by the t test, whereas the Wilcoxon-Mann-Whitney non-parametric test was used to compare medians of non-normally distributed continuous variables. Binomial variables were tested by the chi-squared test or Fisher's exact test. Pearson's correlation coefficient was used to determine the correlations. A p-value of <.05 was considered statistically significant.
| RESULTS
Of the 23 SCA10 patients, 52.17% were male and 47.83% female, with a mean age of 47.3 AE 11.6 years for ataxic patients. The demographic and clinical characteristics of the SCA10 patients and controls are shown in Table 1 . Table 2 ). Sleep-disordered breathing was 9.3 (6.1-16.4) for SCA10 patients and 3.2 (2.6-4.6) for controls (p = .0002) ( Table 2 ). Mean RDI (>5/hr) and prevalence of respiratory disturbance were significantly higher in SCA10 patients than in controls. Nine SCA10 patients with RDI had above-normal BMI. None of the 23 patients had RLS or PLMS.
When the significant sleep disturbances in patients with SCA10 in relation to the controls were correlated with severity parameters of SCA10, it was observed that there was a direct correlation of REM sleep onset with the age of onset of symptoms (r = .459, performed a polysomnographic study of five patients with SCA2 and in four cases observed absence of muscle atony during REM sleep.
Other sleep disorders observed in patients with SCA2 were RBD, RLS and PLMS (Pedroso, Braga-Neto, Fel ıcio, Aquion, et al., 2011; Pedroso, Braga-Neto, Fel ıcio, Dutra, et al., 2011) . Changes in sleep architecture and sleep abnormalities in SCA2 constitute an important marker of the disease.
In the present study, REM sleep disorders were related to a shorter disease time and lower ataxia severity, and also to a later age at onset. This is a pattern of REM sleep similar to that found in Parkinson's disease, but different from SCA2 in which RBD is associated with a greater disease severity (Raggi et al., 2013; Vel azquez-P erez et al., 2011) . SCA3 patients presented with poor sleep efficiency and REM sleep abnormalities as the disease progressed (Chi et al., 2013) . Fragmented sleep in patients with other neurodegenerative diseases, such as Parkinson's disease, SCA2 and SCA3, may share similar pathomechanisms (Chi et al., 2013; Dang & Cunnington, 2010; Raggi et al., 2013) . studies showing reduced striatal dopaminergic activity . However, sleep disorders in neurodegenerative diseases may be associated with more diffuse structural damage in the central nervous system, more specifically to sleep-wake-generating cells and their networking (Raggi et al., 2013; Silva et al., 2016) .
The brainstem circuits known to be associated with RBD pathogenesis come from breakdown of the circuits responsible for REM sleep atonia (subcoeruleus complex, gigantocellular reticular nucleus, dorsal raphe nucleus and peduncolopontine nucleus) . The progressive loss of pons neurons could also influence REM sleep as a result of the degeneration of part of the group of REM neurons that participate in the cholinergic system and present maximal tonus during REM sleep, promoting cortical and limbic activation (Siegel, 2004) . The cerebellum participates in the REM sleep atony, the phasic activity of the lateral rectus muscles of the eyes, and the delta wave inhibition leading to REM sleep desynchronisation and wakefulness (Gadea-Ciria & Fuentes, 1976) . Therefore, cerebellar atrophy would contribute to the reduction in the quantity of REM sleep, and to the absence of atony during REM sleep (DelRosso & Hoque, 2014) .
In our study, the frequency of respiratory disturbances in the SCA10 patients was higher than in the controls. There was no correlation between BMI and sleep obstructive apnea. Rueda et al. (2016) , in a study of 12 patients with SCA6, found a higher incidence of sleep-disordered breathing in patients than in controls. Pedroso, Braga-Neto, Fel ıcio, Aquino, et al. (2011); Pedroso, BragaNeto, Fel ıcio, Dutra, et al. (2011) showed 22.6% of SCA3 patients and no cases in SCA1, SCA2 and SCA6. Speculative pathophysiological mechanisms in SCA3 and sleep obstructive apnea may include dystonia or denervation of the laryngeal muscles, which is absent in SCA10 .
This clinical and polysomnographic study shows that our SCA10 patients had sleep disorders related to shorter disease duration and lower severity of ataxia, in a pattern similar to that of other neurodegenerative diseases. However, a longitudinal study with more patients is required to follow the changes in clinical manifestations and PSG as the disease evolves and study the possible relationship between the SCA mechanism and the mechanism of sleep disorders in SCA10 patients.
AUTHOR CONTRIBU TI ONS
EL planned the project, collected data and wrote the manuscript.
CHFC wrote, corrected and reviewed the manuscript. AZ wrote and reviewed the manuscript. ACC planned, organised and supervised the project and reviewed the manuscript. SR supervised the project and reviewed the manuscript. RPM supervised the project and reviewed the manuscript. TA supervised the project and reviewed the manuscript. HAGT planned, organised and supervised the project, and corrected/reviewed the manuscript.
CONF LICT OF I NTEREST
No conflicts of interest declared.
O R C I D
Carlos H. F. Camargo http://orcid.org/0000-0002-3533-0347
